23 February 2021 - - US-based specialty pharmaceutical company ForDoz Pharma has entered into an agreement with pharmaceutical company LipoMedix for manufacturing its lead compound, pegylated liposomal Promitil (PL-MLP) for a Phase 2 clinical study, the company said.

Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy.

In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug resistant tumors.

ForDoz Pharma Corp. is a privately-owned specialty pharmaceutical company focusing on development, manufacturing, and commercialization of value-added sterile and complex injectable products such as liposomes, microspheres, micelles, nanosuspensions, and microcrystal-suspensions.

ForDoz Pharma is located on the 27-acre campus at greater Princeton area of New Jersey, a prominent pharmaceutical hub in the United States.

At this 27-acre campus, ForDoz Pharma has R and D labs, cGMP QC and microbiology labs and a fully qualified and validated sterile complex injectable product manufacturing facility which complies with both US and EU cGMP standards.

ForDoz Pharma is accelerating and improving traditional drug development processes through proprietary complex injectable drug delivery technology platform with particle sizes ranging from 10 nm to several µm.

At ForDoz Pharma, we can commercialize products as a CDMO partner via a closed loop system, by performing R and D, analytical testing, process scale-up and commercial manufacturing all from our one single campus site.

LipoMedix is a clinical-stage, oncology-focused pharmaceutical company involved in the development of an innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform.

This formulation, known as Promitil, or Pegylated Liposomal Mitomycin-c Prodrug (PL-MLP), overcomes the problems associated with mitomycin-c toxicity and turns it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those of the gastrointestinal tract (stomach, pancreas, colorectal).

The inventor and scientific founder of LipoMedix is Prof. Alberto Gabizon of the Hebrew University Shaare Zedek Medical Center, who is also the co-inventor and co-developer of Doxil, the first FDA-approved nano-drug in cancer therapy.

As co-developer of Doxil, Prof. Gabizon is one of the few scientists who is intimately familiar with the successful development and commercialization process for liposomal drugs.

Rafael Holdings is focused on the development of novel cancer therapies. The company is a significant investor in two clinical-stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. 

Through its wholly-owned Barer Institute subsidiary, the company is developing compounds focused on the regulation of cancer metabolism. The company also holds commercial real estate assets in New Jersey and Jerusalem.